Consensus on the development of vaccines against naturally acquired melioidosis

Direk Limmathurotsakul, Simon G P Funnell, Alfredo Torres, Lisa A. Morici, Paul J. Brett, Susanna Dunachie, Timothy Atkins, Daniel M. Altmann, Gregory Bancroft, Sharon J. Peacock

Research output: Contribution to journalArticle

30 Scopus citations


Several candidates for a vaccine against Burkholderia pseudomallei, the causal bacterium of melioidosis, have been developed, and a rational approach is now needed to select and advance candidates for testing in relevant nonhuman primate models and in human clinical trials. Development of such a vaccine was the topic of a meeting in the United Kingdom in March 2014 attended by international candidate vaccine developers, researchers, and government health officials. The focus of the meeting was advancement of vaccines for prevention of natural infection, rather than for protection from the organism’s known potential for use as a biological weapon. A direct comparison of candidate vaccines in well-characterized mouse models was proposed. Knowledge gaps requiring further research were identified. Recommendations were made to accelerate the development of an effective vaccine against melioidosis.

Original languageEnglish (US)
Pages (from-to)e1-e7
JournalEmerging Infectious Diseases
Issue number6
StatePublished - Jun 1 2015


ASJC Scopus subject areas

  • Epidemiology
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Limmathurotsakul, D., Funnell, S. G. P., Torres, A., Morici, L. A., Brett, P. J., Dunachie, S., Atkins, T., Altmann, D. M., Bancroft, G., & Peacock, S. J. (2015). Consensus on the development of vaccines against naturally acquired melioidosis. Emerging Infectious Diseases, 21(6), e1-e7.